{"title":"Advances in biomarkers in multiple system atrophy.","authors":"Anastasia Bougea","doi":"10.1080/14737159.2025.2489729","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In order to improve illnessidentification, monitoring, and patient outcomes, this special reportemphasizes the revolutionary potential of fluid and imaging biomarkers usingnew diagnostic technologies in Multiple system atrophy (MSA).</p><p><strong>Areas covered: </strong>Innovations like multiplexseeding aggregation assays (SAA), 18FDG-Positron Emission Tomography (PET), andSPECT are changing the diagnostic landscape. These techniques make it easier todetect MSA early and offer noninvasive monitoring choices. Althoughneurofilament light chain measurements in blood and cerebrospinal fluid (CSF),as well as α-synuclein-baseddiagnostic biomarkers in CSF, are recognized as both diagnostic and surrogatemarkers of disease progression in MSA, their application in clinical practiceis limited to research. Some efforts are being made in the development ofselective α- synucleinPET tracers despite numerous barriers in visualizing intracellular localizationof α-synuclein. The primarydrawbacks include the high expense of SAA and imaging technologies, the paucityof multicenter longitudinal investigations, and the lack of uniformity of theprοtocols. The research highlights that to successfully solve these restrictions, stakeholders must continue tocollaborate.</p><p><strong>Expert opinion: </strong>A multi-dimensional biomarkersystem of MSA patients maximizes the power of contemporary diagnostics toenhance MSA care by prioritizing the ongoing evaluation of multi-omics data.</p>","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Molecular Diagnostics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737159.2025.2489729","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: In order to improve illnessidentification, monitoring, and patient outcomes, this special reportemphasizes the revolutionary potential of fluid and imaging biomarkers usingnew diagnostic technologies in Multiple system atrophy (MSA).
Areas covered: Innovations like multiplexseeding aggregation assays (SAA), 18FDG-Positron Emission Tomography (PET), andSPECT are changing the diagnostic landscape. These techniques make it easier todetect MSA early and offer noninvasive monitoring choices. Althoughneurofilament light chain measurements in blood and cerebrospinal fluid (CSF),as well as α-synuclein-baseddiagnostic biomarkers in CSF, are recognized as both diagnostic and surrogatemarkers of disease progression in MSA, their application in clinical practiceis limited to research. Some efforts are being made in the development ofselective α- synucleinPET tracers despite numerous barriers in visualizing intracellular localizationof α-synuclein. The primarydrawbacks include the high expense of SAA and imaging technologies, the paucityof multicenter longitudinal investigations, and the lack of uniformity of theprοtocols. The research highlights that to successfully solve these restrictions, stakeholders must continue tocollaborate.
Expert opinion: A multi-dimensional biomarkersystem of MSA patients maximizes the power of contemporary diagnostics toenhance MSA care by prioritizing the ongoing evaluation of multi-omics data.
期刊介绍：
Expert Review of Molecular Diagnostics (ISSN 1473-7159) publishes expert reviews of the latest advancements in the field of molecular diagnostics including the detection and monitoring of the molecular causes of disease that are being translated into groundbreaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting.
Each issue of Expert Review of Molecular Diagnostics contains leading reviews on current and emerging topics relating to molecular diagnostics, subject to a rigorous peer review process; editorials discussing contentious issues in the field; diagnostic profiles featuring independent, expert evaluations of diagnostic tests; meeting reports of recent molecular diagnostics conferences and key paper evaluations featuring assessments of significant, recently published articles from specialists in molecular diagnostic therapy.
Expert Review of Molecular Diagnostics provides the forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
